Literature DB >> 16199549

The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC).

S Krüger1, A Bier, C Engel, E Mangold, C Pagenstecher, M von Knebel Doeberitz, E Holinski-Feder, G Moeslein, K Schulmann, J Plaschke, J Rüschoff, H K Schackert.   

Abstract

The polymorphic variants at codon 72 of the p53 gene were shown to be functionally distinct in vitro, whereby the arginine (arg) variant induces apoptosis more efficiently than the proline (pro) variant. From the evidence that the DNA mismatch repair system and p53 interact to maintain genomic integrity, we hypothesized that the codon 72 variation may influence the age of onset of disease in HNPCC patients. We tested 538 patients for p53 codon 72 variants, including 167 unrelated patients with pathogenic germline mutations in MSH2 or MLH1 and colorectal carcinoma as first tumour, 126 patients with sporadic microsatellite stable colorectal cancers, and 245 healthy controls. The median age of onset was 41, 36, and 32 years for MSH2 or MLH1 mutation carriers with arg/arg, arg/pro, and pro/pro genotypes, respectively. The log rank test revealed significant differences in the age of onset between arg/arg and pro/pro individuals (p = 0.0002) and in arg/pro versus arg/arg and pro/pro individuals (p = 0.0026 and p = 0.0217, respectively). A Cox regression model indicated an additive mode of inheritance. No significant differences in age of onset were observed among different genotype carriers with microsatellite stable tumours. Our results suggest that p53 codon 72 genotypes are associated with the age of onset of colorectal carcinoma in a mismatch repair deficient background in a dose dependent manner. These findings may be relevant for preventive strategies in HNPCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16199549      PMCID: PMC1735929          DOI: 10.1136/jmg.2004.028506

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  10 in total

1.  MDM2 SNP309 accelerates colorectal tumour formation in women.

Authors:  Gareth L Bond; Chiara Menin; Roberta Bertorelle; Pia Alhopuro; Lauri A Aaltonen; Arnold J Levine
Journal:  J Med Genet       Date:  2006-07-06       Impact factor: 6.318

2.  Polymorphisms of cell cycle regulator genes CCND1 G870A and TP53 C215G: Association with colorectal cancer susceptibility risk in a Malaysian population.

Authors:  Mohd Nizam Zahary; Abdul Aziz Ahmad Aizat; Gurjeet Kaur; Lee Yeong Yeh; Maya Mazuwin; Ravindran Ankathil
Journal:  Oncol Lett       Date:  2015-09-18       Impact factor: 2.967

3.  TP53 alterations and colorectal cancer predisposition in south Indian population: a case-control study.

Authors:  Gopi Krishna Singamsetty; Sravanthi Malempati; Srichandana Bhogadhi; Ravinder Kondreddy; Suresh Govatati; Naveen Kumar Tangudu; Sowdamani Govatati; Anil Kumar kuraganti; Manjula Bhanoori; Kondaiah Kassetty
Journal:  Tumour Biol       Date:  2013-10-26

4.  TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis.

Authors:  Jing-Jun Wang; Yuan Zheng; Liang Sun; Li Wang; Peng-Bo Yu; Jian-Hua Dong; Lei Zhang; Jing Xu; Wei Shi; Yu-Chun Ren
Journal:  Mol Biol Rep       Date:  2010-12-08       Impact factor: 2.316

5.  Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer.

Authors:  Sajid A Khan; Kamran Idrees; Ann Forslund; Zhaoshi Zeng; Shoshana Rosenberg; Hanna Pincas; Francis Barany; Kenneth Offit; Michael P Laquaglia; Philip B Paty
Journal:  J Surg Oncol       Date:  2008-06-01       Impact factor: 3.454

6.  Implication of DNA repair genes in prostate tumourigenesis in Indian males.

Authors:  Anju Bansal; Abha Soni; Punita Rao; L C Singh; Ashwani Kumar Mishra; N K Mohanty; Sunita Saxena
Journal:  Indian J Med Res       Date:  2012-10       Impact factor: 2.375

7.  What's your poison? Impact of individual repair capacity on the outcomes of genotoxic therapies in cancer. Part II - information content and validity of biomarkers for individual repair capacity in the assessment of outcomes of anticancer therapy.

Authors:  Rumena Petkova; Pavlina Chelenkova; Elena Georgieva; Stoian Chakarov
Journal:  Biotechnol Biotechnol Equip       Date:  2014-01-02       Impact factor: 1.632

8.  TP53 Polymorphisms and Colorectal Cancer Risk in Patients with Lynch Syndrome in Taiwan: A Retrospective Cohort Study.

Authors:  Abram Bunya Kamiza; Ling-Ling Hsieh; Reiping Tang; Huei-Tzu Chien; Chih-Hsiung Lai; Li-Ling Chiu; Tsai-Ping Lo; Kuan-Yi Hung; Jeng-Fu You; Wen-Chang Wang; Chao A Hsiung; Chih-Ching Yeh
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

9.  The association between the TP53 Arg72Pro polymorphism and colorectal cancer: An updated meta-analysis based on 32 studies.

Authors:  Xin Tian; Shundong Dai; Jing Sun; Shenyi Jiang; Youhong Jiang
Journal:  Oncotarget       Date:  2017-01-03

10.  MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians.

Authors:  Joerg Bittenbring; Frédérique Parisot; Alain Wabo; Monika Mueller; Lynn Kerschenmeyer; Markus Kreuz; Lorenz Truemper; Olfert Landt; Alain Menzel; Michael Pfreundschuh; Klaus Roemer
Journal:  BMC Cancer       Date:  2008-04-23       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.